Molecular oncology and the neoadjuvant setting: The perfect blend for treatment personalization and clinical trial design

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 67-70

  Generali, Daniele ^a   Berruti, Alfredo ^b   Foroni, Chiara ^a   Bazzola, Letizia ^a   Andreis, Daniele ^a   Allevi, Giovanni ^a   Bersiga, Alessandra ^a   Dogliotti, Luigi ^b   Fox, Stephen B ^c   Harris, Adrian L ^d   Bottini, Alberto ^a  

^a CREMONA HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FLUOROURACIL; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TUMOR MARKER; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; GENE EXPRESSION PROFILING; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PERSONALIZED MEDICINE; REPRODUCIBILITY; STANDARD; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; NEOADJUVANT THERAPY; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855185406     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr029     Document Type: Article

References (26)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
2. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
4. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
5. Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009;9(5):417-422.
6. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
7. Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006;3(10):540-551.
8. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7(4):347-350.
9. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
10. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(19):3039-3047.
11. Geyer FC, Marchio C, Reis-Filho JS. The role of molecular analysis in breast cancer. Pathology. 2009;41(1):77-88.
12. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996;37(9):1438-1444.
13. Generali D, Bates G, Berruti A, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15(3):1046-1051.
14. Generali D, Buffa FM, Berruti A, et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009;27(2):227-234.
15. Generali D, Fox SB, Brizzi MP, et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res. 2008;14(9):2673-2680.
16. Baker AF, Dragovich T, Ihle NT, et al. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res. 2005;11(12):4338-4340.
17. Espina V, Edmiston KH, Heiby M, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 2008;7(10):1998-2018.
18. Liedtke C, Wang J, Tordai A, et al. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat. 2010;121(2):301-309.
19. Jones RL, Salter J, A'Hern R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010;119(2):315-323.
20. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
21. Carney WP, Neumann R, Lipton A, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003;49(10):1579-1598.
22. Smith BM, Slade MJ, English J, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol. 2000;18(7):1432-1439.
23. Cristofanilli M, Braun S. Circulating tumor cells revisited. JAMA. 2010;303(11):1092-1093.
24. Salter KH, Acharya CR, Walters KS, et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One. 2008;3(4):e1908.
25. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672-675.
26. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010;28(16):2777-2783.